{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:37:26Z","timestamp":1793655446102,"version":"4.5.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"National Centre for Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejpb.2024.114300","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T16:36:29Z","timestamp":1714494989000},"page":"114300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":false,"given":"Lukasz","family":"Kuryk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mathlouthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-5131","authenticated-orcid":false,"given":"Magdalena","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-1297","authenticated-orcid":false,"given":"Beata","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-8667","authenticated-orcid":false,"given":"Alessio","family":"Malfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2499-5490","authenticated-orcid":false,"given":"Francesca","family":"Mastrotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-5909","authenticated-orcid":false,"given":"Stefano","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-9944","authenticated-orcid":false,"given":"Paolo","family":"Caliceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7826","authenticated-orcid":false,"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2018","key":"10.1016\/j.ejpb.2024.114300_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejpb.2024.114300_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejpb.2024.114300_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejpb.2024.114300_b0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2024.114300_b0025","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114300_b0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jss.2010.04.015","article-title":"Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer","volume":"163","author":"Kennedy","year":"2010","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ejpb.2024.114300_b0035","doi-asserted-by":"crossref","first-page":"e000357","DOI":"10.1136\/esmoopen-2018-000357","article-title":"How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies","volume":"3","author":"Park","year":"2018","journal-title":"ESMO Open"},{"issue":"Suppl 6","key":"10.1016\/j.ejpb.2024.114300_b0040","first-page":"vi56-65","article-title":"Emerging targeted therapies in triple-negative breast cancer","volume":"23","author":"Crown","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2024.114300_b0045","doi-asserted-by":"crossref","first-page":"1259314","DOI":"10.3389\/fonc.2023.1259314","article-title":"Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model","volume":"13","author":"Garofalo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114300_b0050","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ijc.30228","article-title":"Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040547","article-title":"Combination therapy of novel oncolytic adenovirus with Anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114300_b0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2023.01.002","article-title":"Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models","volume":"28","author":"Kuryk","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ejpb.2024.114300_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030621","article-title":"Optimization of early steps in oncolytic adenovirus ONCOS-401 production in T-175 and HYPERFlasks","volume":"20","author":"Kuryk","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114300_b0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41417-018-0038-x","article-title":"Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401","volume":"26","author":"Kuryk","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejpb.2024.114300_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13070949","article-title":"Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114300_b0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot study of ONCOS-102 and Pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in Anti\u2013PD-1\u2013resistant advanced melanoma","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114300_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.916839","article-title":"Novel insights into mesothelioma therapy: emerging avenues and future prospects","volume":"12","author":"Kuryk","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114300_b0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2024.114300_b0095","doi-asserted-by":"crossref","unstructured":"O. Moaven, W.M. C, A.S. J, P.Z. Anastasiadis, M.J. Borad, Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice, JCO Precis. Oncol., 5 (2021).","DOI":"10.1200\/PO.20.00395"},{"key":"10.1016\/j.ejpb.2024.114300_b0100","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jmv.25501","article-title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma","volume":"91","author":"Kuryk","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejpb.2024.114300_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2024.114300_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168878","article-title":"Rationale and clinical research progress on PD-1\/PD-L1-based immunotherapy for metastatic triple-negative breast cancer","volume":"23","author":"Ren","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114300_b0115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2024.114300_b0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10555-021-09972-4","article-title":"Checkpoint inhibitor therapy for metastatic triple-negative breast cancer","volume":"40","author":"Heeke","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejpb.2024.114300_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910522","article-title":"Concepts in oncolytic adenovirus therapy","volume":"22","author":"Mantwill","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114300_b0130","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202307756","article-title":"Synergistic approach to combat triple-negative breast cancer: B7\u2013H4 checkpoint-based photodynamic nanodrug coupled with neutrophil extracellular trap regulation","volume":"33","author":"Jiang","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2024.114300_b0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40364-021-00318-4","article-title":"Oncolytic viruses for triple negative breast cancer and beyond","volume":"9","author":"Jin","year":"2021","journal-title":"Biomark Res."},{"key":"10.1016\/j.ejpb.2024.114300_b0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","article-title":"Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives","volume":"50","author":"Schettini","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2024.114300_b0145","doi-asserted-by":"crossref","first-page":"e23647","DOI":"10.4161\/tisb.23647","article-title":"Overcoming physical barriers in cancer therapy","volume":"1","author":"Beyer","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejpb.2024.114300_b0150","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114300_b0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/OP.22.00483","article-title":"Role of immunotherapy in breast cancer","volume":"19","author":"Jacob","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejpb.2024.114300_b0160","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122501","article-title":"Improving aqueous solubility of paclitaxel with polysarcosine-b-poly(gamma-benzyl glutamate) nanoparticles","volume":"631","author":"Lebleu","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114300_b0170","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jcis.2023.04.164","article-title":"Are all poorly soluble drugs dissolved in deep eutectic solvents true solutions?","volume":"645","author":"Zhu","year":"2023","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2024.114300_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26030601","article-title":"Evaluation of poorly soluble drugs' dissolution rate by laser scattering in different water isotopologues","volume":"26","author":"Uspenskaya","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2024.114300_b0180","doi-asserted-by":"crossref","first-page":"e1532763","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model","volume":"8","author":"Kuryk","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejpb.2024.114300_b0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41523-019-0108-8","article-title":"Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy","volume":"5","author":"Theodossiou","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0190","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1002\/pmic.201000811","article-title":"Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics","volume":"11","author":"Tian","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.ejpb.2024.114300_b0195","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation - turning cold tumours into hot","volume":"13","author":"Garofalo","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0200","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jmv.25677","article-title":"Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor","volume":"92","author":"Kuryk","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejpb.2024.114300_b0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bcp.2017.07.020","article-title":"Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species","volume":"143","author":"Allison","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114300_b0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13058-016-0744-y","article-title":"Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment","volume":"18","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2024.114300_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121969","article-title":"Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-alpha monoclonal antibody","volume":"624","author":"Liu","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114300_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120789","article-title":"Paclitaxel's mechanistic and clinical effects on breast cancer","volume":"9","author":"Abu Samaan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2024.114300_b0225","doi-asserted-by":"crossref","first-page":"e1637188","DOI":"10.1080\/2162402X.2019.1637188","article-title":"Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade","volume":"8","author":"Kepp","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejpb.2024.114300_b0230","doi-asserted-by":"crossref","first-page":"18380","DOI":"10.1038\/s41598-023-45144-w","article-title":"Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations","volume":"13","author":"Abbas","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2024.114300_b0235","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2024.114300_b0240","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/drup.2001.0218","article-title":"Breast cancer response to paclitaxel in vivo","volume":"4","author":"Symmans","year":"2001","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ejpb.2024.114300_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovic","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2024.114300_b0250","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T Cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines (basel)"},{"key":"10.1016\/j.ejpb.2024.114300_b0255","doi-asserted-by":"crossref","first-page":"2200094","DOI":"10.1002\/gch2.202200094","article-title":"Combining of oncolytic virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic","volume":"7","author":"Zou","year":"2023","journal-title":"Glob. Chall."},{"key":"10.1016\/j.ejpb.2024.114300_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0265","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0270","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3389\/fonc.2020.01543","article-title":"Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies","volume":"10","author":"Saraiva","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114300_b0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13578-022-00887-3","article-title":"Three-dimensional in vitro culture models in oncology research","volume":"12","author":"Jubelin","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejpb.2024.114300_b0280","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114300_b0285","doi-asserted-by":"crossref","first-page":"e30534","DOI":"10.1097\/MD.0000000000030534","article-title":"Effect of pembrolizumab on T lymphocyte subsets in patients with advanced oral cancer and its therapeutic effect","volume":"101","author":"Feng","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejpb.2024.114300_b0290","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2024.114300_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186828","article-title":"Adenovirus receptor expression in cancer and its multifaceted role in oncolytic adenovirus therapy","volume":"21","author":"Hensen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114300_b0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejpb.2024.114300_b0305","doi-asserted-by":"crossref","first-page":"e6903","DOI":"10.7717\/peerj.6903","article-title":"Expression of ICOSL is associated with decreased survival in invasive breast cancer","volume":"7","author":"Wang","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.ejpb.2024.114300_b0310","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejpb.2024.114300_b0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejpb.2024.114300_b0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:21:48Z","timestamp":1715944908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":64,"alternative-id":["S0939641124001267"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114300","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114300"}}